Locoregional melanoma metastases resistant to PD-1 inhibitor therapy treated with intralesional talimogene laherparepvec

Locoregional melanoma metastases resistant to PD-1 inhibitor therapy treated with intralesional talimogene laherparepvec

Bibliographic Details
Main Authors:	Matthew M. Wallace, MD, John A. Zitelli, MD
Format:	Article
Language:	English
Published:	Elsevier 2024-01-01
Series:	JAAD Case Reports
Subjects:	melanoma Mohs surgery talimogene laherparepvec
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352512623004095

Similar Items

Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma
by: Pier Francesco Ferrucci, et al.
Published: (2021-03-01)

Inflammatory melanoma in transit metastases with complete response to talimogene laherparepvec
by: Jonathan T. Blackmon, et al.
Published: (2017-07-01)

Durable melanoma control following disseminated talimogene laherparepvec herpetic infection
by: Leonid Shmuylovich, MD, PhD, et al.
Published: (2022-11-01)

Inflammatory Colitis after Treatment of Melanoma with Talimogene Laherparepvec (T-VEC)
by: Jennifer Gardner, et al.
Published: (2018-07-01)

Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma
by: Robert H. I. Andtbacka, et al.
Published: (2019-06-01)

Liver transplant patient with in-transit squamous cell carcinoma treated with talimogene laherparepvec
by: Jamie Lebhar, BME, et al.
Published: (2023-10-01)

Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition
by: Zoë Blake, et al.
Published: (2018-04-01)

Complete remission from intralesional talimogene laherparepvec for regionally advanced Merkel cell carcinoma in an immunocompromised solid organ transplant patient
by: Kelsey E. Hirotsu, MD, et al.
Published: (2021-07-01)

Talimogene Laherparepvec in Advanced Mucosal Melanoma of the Urethra Upon Primary Resistance on Immune Checkpoint Inhibition: A Case Report
by: Anne Fröhlich, et al.
Published: (2020-05-01)

Kaposi’s varicelliform eruption in a patient with metastatic melanoma and primary cutaneous anaplastic large cell lymphoma treated with talimogene laherparepvec and nivolumab
by: David M. Miller, et al.
Published: (2018-11-01)

Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells
by: Jens Tijtgat, et al.
Published: (2021-10-01)

Activity of TNT: a phase 2 study using talimogene laherparepvec, nivolumab and trabectedin for previously treated patients with advanced sarcomas (NCT# 03886311)
by: Sant P. Chawla, et al.
Published: (2023-05-01)

Talimogene laherparepvec: First in class oncolytic virotherapy
by: Robert M. Conry, et al.
Published: (2018-04-01)

Use of Talimogene Laherparepvec to Treat Cutaneous Squamous Cell Carcinoma in a Renal Transplant Patient
by: Max Miller, et al.
Published: (2023-06-01)

A phase 1, first-in-child, multicenter study to evaluate the safety and efficacy of the oncolytic herpes virus talimogene laherparepvec in pediatric patients with advanced solid tumors
by: Lucas Moreno, et al.
Published: (2023-05-01)

Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial
by: Maartje W. Rohaan, et al.
Published: (2022-08-01)

Beyond Immunotherapy: Seizing the Momentum of Oncolytic Viruses in the Ideal Platform of Skin Cancers
by: Dimitrios C. Ziogas, et al.
Published: (2022-06-01)

Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials
by: Howard L. Kaufman, et al.
Published: (2017-09-01)

Efficacy of Oncolytic Herpes Simplex Virus T-VEC Combined with BET Inhibitors as an Innovative Therapy Approach for NUT Carcinoma
by: Paul V. Ohnesorge, et al.
Published: (2022-06-01)

Clitoral metastasis of vulvar melanoma treated with talimogene laherparepvec
by: Erin M. McClure, BS, et al.
Published: (2023-02-01)

Complete resolution of PD-1 refractory, locoregionally advanced Merkel cell carcinoma with talimogene laherparepvec
by: Neha Singh, BS, et al.
Published: (2023-06-01)

Oncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus H-1
by: Markus eMoehler, et al.
Published: (2014-05-01)

Genomic Signature of the Natural Oncolytic Herpes Simplex Virus HF10 and Its Therapeutic Role in Preclinical and Clinical Trials
by: Ibrahim Ragab Eissa, et al.
Published: (2017-07-01)

Tumoral melanosis mimicking residual melanoma in the setting of talimogene laherparepvec treatment
by: Jennifer Gardner, et al.
Published: (2022-10-01)

Efficacy of talimogene laherparepvec (T-VEC) in melanoma patients (pts) with locoregional (LR) recurrence, including in-transit metastases (ITM): Subgroup analysis of the phase III OPTiM study
by: Middleton, M, et al.
Published: (2019)

Four cases of disseminated herpes simplex virus following talimogene laherparepvec injections for unresectable metastatic melanoma
by: Kate E. Beekman, BS, et al.
Published: (2023-03-01)

Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanomaResearch in context
by: Robert H.I. Andtbacka, et al.
Published: (2019-09-01)

Talimogene Laherparepvec: Moving From First-In-Class to Best-In-Class
by: Howard L. Kaufman, et al.
Published: (2022-02-01)

Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series
by: Lillian Sun, et al.
Published: (2018-05-01)

Mohs micrographic surgery for melanoma: A convincing treatment modality
by: Stephanie Clements, et al.
Published: (2022-01-01)

Current perspectives on Mohs micrographic surgery for melanoma
by: Beaulieu D, et al.
Published: (2018-06-01)

Correction: Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany
Published: (2021-10-01)

Induced Vitiligo due to Talimogene Laherparepvec Injection for Metastatic Melanoma Associated with Long-term Complete Response
by: Pablo Iglesias, et al.
Published: (2018-11-01)

Talimogene Laherparepvec (T-VEC): A Review of the Recent Advances in Cancer Therapy
by: Tiantian Zhang, et al.
Published: (2023-01-01)

Advances in Intralesional Therapy for Locoregionally Advanced and Metastatic Melanoma: Five Years of Progress
by: Danielle K. DePalo, et al.
Published: (2023-02-01)

Mohs surgery for melanoma treatment: a systematic literature review
by: Juliana Reis de Sousa Zacarias, et al.
Published: (2023-10-01)

Mohs micrographic surgery versus wide local excision for head and neck melanoma-in-situ
by: Kevin Phan, et al.
Published: (2020-08-01)

Implementation of immunohistochemical staining among mohs micrographic surgeons
by: Samantha K. Sarlin, et al.
Published: (2022-06-01)

Disease-specific survival of malignant melanoma after Mohs micrographic surgery is not impacted by initial margins: A systematic review and meta-analysisCapsule Summary
by: Olivia M. Crum, MD, et al.
Published: (2023-12-01)

Mohs surgery for the treatment of lentigo maligna and lentigo maligna melanoma – a systematic review
by: Ajay N. Sharma, et al.
Published: (2021-02-01)